OBIO
Orchestra BioMed·NASDAQ
--
--(--)
--
--(--)
5.48 / 10
Netural
The analyst community is overwhelmingly bullish with a 100% Buy composition, yet fund-flow trends are negative across block, medium, and large sizes. This tug-of-war results in a netural sentiment overall. Investors may interpret the single-analyst endorsement as tentative optimism, but the negative fund-flow backdrop cautions against aggressive entry.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionBarclays
Times predicted3
Historical Win Rate66.7%
What is the analyst consensus for OBIO?
- OBIO holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.48/10 (Netural).
